CMS advises SYNLAB on the sale of its Swiss business to Sonic Healthcare
SYNLAB and Sonic have announced the sale of SYNLAB Suisse SA to Sonic Healthcare for a purchase price of CHF 150m, having received the required approval of the Swiss antitrust authority. Closing of the transaction expected for 3 July 2023.
SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates. SYNLAB operates in 35 countries across four continents and holds leading positions in most markets.
A team of CMS Switzerland, comprising Alain Raemy (Partner) and Florian Jung (Senior Associate; both corporate/M&A) as well as Marquard Christen (Partner) and Hadi Mirzai (Senior Associate; both competition/merger control) has advised on all legal aspects of the transaction, in cooperation with SYNLAB's inhouse legal team, consisting of Dr Fabian Walla (Group General Counsel & Chief Compliance Officer) and Dr Peter Macheiner (Head Legal M&A and Procurement).
CMS
Alain Raemy (Partner, Corporate M&A)
Florian Jung (Senior Associate, Corporate/M&A)
Marquard Christen (Partner, Competition / Merger Control)
Hadi Mirzai (Senior Associate, Competition / Merger Control)
SYNLAB
Dr. Fabian Walla (Group General Counsel & Chief Compliance Officer)
MMag. Dr. Peter Macheiner (Head Legal M&A and Procurement)
